Rechallenge with platinum chemo after tarlatamab for small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a second round of platinum-based chemotherapy (carboplatin and etoposide) can help patients whose extensive-stage small-cell lung cancer has progressed while on tarlatamab. It aims to see if this approach can control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have extensive-stage small-cell lung cancer that has gotten worse after at least 90 days from your first platinum-based chemotherapy.
- You are currently on or have recently been on tarlatamab, and your cancer has progressed while on it.
- You must be able to provide a tumor sample (either a new biopsy or an archived one) taken after the progression on tarlatamab.
- You should have good performance status (able to do light work or be fully active) and adequate organ function (like kidney and blood counts).
- You must not have had more than one prior chemotherapy regimen for your extensive-stage disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
Hear when a new Extensive Disease Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.